Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk.

Kwon EM, Holt SK, Fu R, Kolb S, Williams G, Stanford JL, Ostrander EA.

Cancer Epidemiol. 2012 Aug;36(4):347-53. doi: 10.1016/j.canep.2012.04.002. Epub 2012 Apr 26.

2.

JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.

Slattery ML, Lundgreen A, Kadlubar SA, Bondurant KL, Wolff RK.

Mol Carcinog. 2013 Feb;52(2):155-66. doi: 10.1002/mc.21841. Epub 2011 Nov 28.

3.

The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.

Vaarala MH, Mattila H, Ohtonen P, Tammela TL, Paavonen TK, Schleutker J.

Int J Cancer. 2008 Jun 1;122(11):2511-6. doi: 10.1002/ijc.23425.

4.

Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population.

Ferguson LR, Han DY, Fraser AG, Huebner C, Lam WJ, Morgan AR, Duan H, Karunasinghe N.

Mutat Res. 2010 Aug 7;690(1-2):108-15. doi: 10.1016/j.mrfmmm.2010.01.017. Epub 2010 Jan 28.

PMID:
20109474
5.

Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans.

Bensen JT, Xu Z, Smith GJ, Mohler JL, Fontham ET, Taylor JA.

Prostate. 2013 Jan;73(1):11-22. doi: 10.1002/pros.22532. Epub 2012 May 1.

6.

Genetic variation in the JAK/STAT/SOCS signaling pathway influences breast cancer-specific mortality through interaction with cigarette smoking and use of aspirin/NSAIDs: the Breast Cancer Health Disparities Study.

Slattery ML, Lundgreen A, Hines LM, Torres-Mejia G, Wolff RK, Stern MC, John EM.

Breast Cancer Res Treat. 2014 Aug;147(1):145-58. doi: 10.1007/s10549-014-3071-y. Epub 2014 Aug 8.

7.

Novel associations of UDP-glucuronosyltransferase 2B gene variants with prostate cancer risk in a multiethnic study.

Vidal AC, Tucker C, Schildkraut JM, Richardson RM, McPhail M, Freedland SJ, Hoyo C, Grant DJ.

BMC Cancer. 2013 Nov 22;13:556. doi: 10.1186/1471-2407-13-556.

8.

Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.

Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Parnes HL, Schenk JM, Tangen CM, Thompson IM, Reichardt JK, Figg WD.

Cancer. 2016 Aug 1;122(15):2332-40. doi: 10.1002/cncr.30071. Epub 2016 May 10.

9.

JAK1, but not JAK2 and STAT3, confers susceptibility to Vogt-Koyanagi-Harada (VKH) syndrome in a Han Chinese population.

Hu K, Hou S, Li F, Xiang Q, Kijlstra A, Yang P.

Invest Ophthalmol Vis Sci. 2013 May 9;54(5):3360-5. doi: 10.1167/iovs.13-11615.

PMID:
23611997
10.

Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors.

Mononen N, Seppälä EH, Duggal P, Autio V, Ikonen T, Ellonen P, Saharinen J, Saarela J, Vihinen M, Tammela TL, Kallioniemi O, Bailey-Wilson JE, Schleutker J.

Cancer Res. 2006 Jan 15;66(2):743-7.

11.

Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analyses.

Lu Y, Sun J, Kader AK, Kim ST, Kim JW, Liu W, Sun J, Lu D, Feng J, Zhu Y, Jin T, Zhang Z, Dimitrov L, Lowey J, Campbell K, Suh E, Duggan D, Carpten J, Trent JM, Gronberg H, Zheng SL, Isaacs WB, Xu J.

Prostate. 2012 Mar;72(4):376-85. doi: 10.1002/pros.21439. Epub 2011 Jun 10.

12.

Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry.

Pal P, Xi H, Guha S, Sun G, Helfand BT, Meeks JJ, Suarez BK, Catalona WJ, Deka R.

Prostate. 2009 Oct 1;69(14):1548-56. doi: 10.1002/pros.20999.

13.

Genetic polymorphisms in inflammation pathway genes and prostate cancer risk.

Kwon EM, Salinas CA, Kolb S, Fu R, Feng Z, Stanford JL, Ostrander EA.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):923-33. doi: 10.1158/1055-9965.EPI-10-0994. Epub 2011 Mar 23.

14.

Putative Prostate Cancer Risk SNP in an Androgen Receptor-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites.

Bu H, Narisu N, Schlick B, Rainer J, Manke T, Schäfer G, Pasqualini L, Chines P, Schweiger MR, Fuchsberger C, Klocker H.

Hum Mutat. 2016 Jan;37(1):52-64. doi: 10.1002/humu.22909. Epub 2015 Oct 19.

15.

Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.

Han JH, Lee YS, Kim HJ, Lee SY, Myung SC.

Asian J Androl. 2015 Mar-Apr;17(2):285-91. doi: 10.4103/1008-682X.133320.

16.

Replication of prostate cancer risk loci in a Japanese case-control association study.

Yamada H, Penney KL, Takahashi H, Katoh T, Yamano Y, Yamakado M, Kimura T, Kuruma H, Kamata Y, Egawa S, Freedman ML.

J Natl Cancer Inst. 2009 Oct 7;101(19):1330-6. doi: 10.1093/jnci/djp287. Epub 2009 Sep 2.

PMID:
19726753
17.

Prostate Cancer in African American Men: The Effect of Androgens and microRNAs on Epidermal Growth Factor Signaling.

Nwaneri AC, McBeth L, Hinds TD Jr.

Horm Cancer. 2016 Dec;7(5-6):296-304. Epub 2016 Jul 22. Review.

PMID:
27447901
18.

Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression.

Lévesque É, Huang SP, Audet-Walsh É, Lacombe L, Bao BY, Fradet Y, Laverdière I, Rouleau M, Huang CY, Yu CC, Caron P, Guillemette C.

Clin Cancer Res. 2013 Feb 1;19(3):699-709. doi: 10.1158/1078-0432.CCR-12-2812. Epub 2012 Nov 27.

19.

Investigation and analysis of single nucleotide polymorphisms in Janus kinase/signal transducer and activator of transcription genes with leukemia.

Zhong Y, Wu J, Chen B, Ma R, Cao H, Wang Z, Cheng L, Ding J, Feng J.

Leuk Lymphoma. 2012 Jun;53(6):1216-21. doi: 10.3109/10428194.2011.645212. Epub 2012 Jan 11.

PMID:
22126101
20.

Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.

Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):969-78.

Supplemental Content

Support Center